Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）

Inclusion Criteria: * Patients with acute ischemic stroke within 3 hours of onset, with a clearly defined time of onset. * Patients who have been revealed to have occlusion on one side of the middle cerebral artery (M1 or M2 portion) on MRA before the start of treatment. * Patients for whom consent has been obtained from either themselves or from their legally acceptable representatives in written form. Exclusion Criteria: * Patients with very light neurological symptoms (an NIHSS score of \<= 4) or with rapidly improving symptoms before the start of treatment. * Patients with serious neurological disorders (an NIHSS score of \>= 23), or serious consciousness disorders (a Japan Coma Scale score of \>= 100) before the start of treatment. * Patients with functional disorders (a mRS score of \>= 2) before stroke onset. * Patients who have been administered drugs that are not allowed to be administered concomitantly with alteplase (other thrombolytic agents) after the stroke onset. * Patients who have been revealed to have extensive early ischemic change (an Alberta Stroke Program Early CT score of \<= 6) on computed tomography (CT) before treatment. * Patients who have been revealed to have obvious occlusion in the blood vessel except for the middle cerebral artery on MRA before treatment. * Patients who are forbidden to undergo magnetic resonance imaging (MRI). * Patients who are defined as having cerebral hemorrhage or subarachnoid hemorrhage (SAH) on CT before treatment. *…